Hello, my name is Dr. Larisa Geskin. I am the Director of Cutaneous Oncology and Photopheresis Unit at the University of Pittsburgh School of Medicine. This presentation will discuss the THERAKOS photopheresis procedure.
THERAKOS Photopheresis is a therapy designed to reduce the skin symptoms associated with cutaneous T-cell lymphoma, also referred to as CTCL.1
This treatment is thought to help restore your body’s natural ability to maintain a balanced immune system.3 More information can be found on this web site in the Patient Brochure.
As shown on the slide as step 1, at the beginning of a THERAKOS Photopheresis treatment session an intravenous line, or IV, is inserted into your arm. Blood is then withdrawn by the Photopheresis instrument.1
This blood enters the photopheresis instrument, which separates the white blood cells that are involved in the immune response from the other components of your blood - this is shown as step 2. The white blood cells remain in the instrument.1
In step 3, a medicine is added to the separated white blood cells. In step 4, the cells are exposed to ultraviolet-A, or UVA, light, which activates the medicine. The treated white blood cells are then returned to your body (shown as step 5).1
This drawing shows the entire process of THERAKOS Photopheresis at a glance. In step 1, the instrument draws a small amount of your blood. In step 2, the blood is separated. In step 3, the medicaton is added to the white blood cells. In step 4 the medication is activated by UVA light. Finally, in step 5, the treated white blood cells are returned to your body.4
Photopheresis is performed in repeated treatments intended to reduce your symptoms over time. Each patient’s treatment schedule and length of treatment varies and will be determined by your doctor.1 Response times can vary between patients, so it is important to follow your doctor’s instructions.1
THERAKOS Photopheresis has an established safety profile with more than a half-million patient treatments.1 Serious side effects are rare, and include fever, worsening of skin redness, and a drop in blood pressure during treatment.5 These side effects usually resolve within one day. Photopheresis does not cause suppression of the immune system.2,3 Ask your doctor if you have questions about the safety of this treatment.
Please see the complete Prescribing Information and Important Safety Information on this web site.
Specially designed for medical professionals to use in their practice.
See top Opinion Leaders address FAQs about THERAKOS™ Photopheresis
Methoxsalen Sterile Solution is indicated for extracorporeal administration with the THERAKOS™ UVAR XTS® or THERAKOS™ CELLEX® Photopheresis System in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment.
Methoxsalen should be used only by physicians who have special training in the THERAKOS™ UVAR XTS® or THERAKOS™ CELLEX® Photopheresis Systems. Methoxsalen is contraindicated in patients exhibiting idiosyncratic reactions to psoralen compounds, patients with a specific history of a light sensitive disease, or patients with aphakia.
THERAKOS™ Photopheresis is not appropriate for patients who cannot tolerate extracorporeal volume loss or shifts, or patients with coagulation disorders. See Important Safety Information for additional details.